Clinical Features of Docetaxel Chemotherapy-Related Lymphedema

Park, Sae In; Jeon, Woo Hyun; Jeung, Ho Joong; Kim, Ghi Chan; Kim, Dong Kyu; Sim, Young-Je

doi:10.1089/lrb.2013.0037

Cited by 12 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This review included studies comparing generalized edema in docetaxel and docetaxel-free groups, but did not specifically report on lymphedema of the arm. The relationship between docetaxel and upper extremity lymphedema is unclear, as the only studies in the literature examining this are case reports [ 58 , 59 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort

Swaroop

Ferguson

Horick

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

Taxane-based chemotherapy for the treatment of breast cancer is associated with fluid retention in the extremities; however, its association with development of breast cancer-related lymphedema is unclear. We sought to determine if adjuvant taxane-based chemotherapy increased risk of lymphedema or mild swelling of the upper extremity. 1121 patients with unilateral breast cancer were prospectively screened for lymphedema with perometer measurements. Lymphedema was defined as a relative volume change (RVC) of ≥10 % from preoperative baseline. Mild swelling was defined as RVC 5- <10 %. Clinicopathologic characteristics were obtained via medical record review. Kaplan–Meier and Cox proportional hazard analyses were performed to determine lymphedema rates and risk factors. 29 % (324/1121) of patients were treated with adjuvant taxane-based chemotherapy. The 2-year cumulative incidence of lymphedema in the overall cohort was 5.27 %. By multivariate analysis, axillary lymph node dissection (ALND) (p < 0.0001), higher body mass index (p = 0.0007), and older age at surgery (p = 0.04) were significantly associated with increased risk of lymphedema; however, taxane chemotherapy was not significant when compared to no chemotherapy and non-taxane chemotherapy (HR 1.14, p = 0.62; HR 1.56, p = 0.40, respectively). Chemotherapy with docetaxel was significantly associated with mild swelling on multivariate analysis in comparison to both no chemotherapy and non-taxane chemotherapy groups (HR 1.63, p = 0.0098; HR 2.15, p = 0.02, respectively). Patients who receive taxane-based chemotherapy are not at an increased risk of lymphedema compared to patients receiving no chemotherapy or non-taxane adjuvant chemotherapy. Those treated with docetaxel may experience mild swelling, but this does not translate into subsequent lymphedema.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort

Swaroop

Ferguson

Horick

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…In most situations, several mechanisms may occur and contribute synergistically to oedema genesis. In addition to aggressive fluid resuscitation and preparation T A B L E 1 Causes of peripheral edema 10,12 Mechanism Cause Force involved Increased capillary permeability (as these drugs are responsible for capillary leak syndrome) Taxanes: 38,39 docetaxel, paclitaxel -increased capillary permeability 38,39 -lymphedema 40,41 through antilymphangiogenic effects of VEGFR-3/VEGFC pathway inhibition 40 -heart failure 4 Protein kinase inhibitors ALK: 42…”

Section: Drug-induced Peripheral Oedemamentioning

confidence: 99%

Drug‐induced peripheral oedema: An aetiology‐based review

Largeau

Cracowski

Lengelle

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Fluid retention, likely due to capillary protein leakage, has been seen in patients treated with docetaxel, and may manifest as peripheral oedema and as pleural and pericardial effusions [ 50 ]. Platinum-based agents carry an increased risk of thrombus formation [ 51 ].…”

Section: Complications Associated With Treatment: the Role Of Imagingmentioning

confidence: 99%

Systemic treatment in breast cancer: a primer for radiologists

et al. 2015

View full text Add to dashboard Cite

Cytotoxic chemotherapy, hormonal therapy and molecular targeted therapy are the three major classes of drugs used to treat breast cancer. Imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), 18F-FDG positron emission tomography (PET)/CT and bone scintigraphy each have a distinct role in monitoring response and detecting drug toxicities associated with these treatments. The purpose of this article is to elucidate the various systemic therapies used in breast cancer, with an emphasis on the role of imaging in assessing treatment response and detecting treatment-related toxicities.Teaching Points• Cytotoxic chemotherapy is often used in combination with HER2-targeted and endocrine therapies.• Endocrine and HER2-targeted therapies are recommended in hormone-receptor- and HER2-positive cases.• CT is the workhorse for assessment of treatment response in breast cancer metastases.• Alternate treatment response criteria can help in interpreting pseudoprogression in metastasis.• Unique toxicities are associated with cytotoxic chemotherapy and with endocrine and HER2-targeted therapies.

show abstract

Clinical Features of Docetaxel Chemotherapy-Related Lymphedema

Cited by 12 publications

References 13 publications

Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort

Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort

Drug‐induced peripheral oedema: An aetiology‐based review

Systemic treatment in breast cancer: a primer for radiologists

Contact Info

Product

Resources

About